Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQZ2451 + metformin
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
TQZ2451 + metformin is a combination regimen used for the treatment of type 2 diabetes mellitus. TQZ2451 is administered as a subcutaneous injection, while metformin hydrochloride is taken orally in sustained-release tablet form. The mechanism of action of TQZ2451 appears to be similar to that of GLP-1 receptor agonists, enhancing glucose-dependent insulin secretion, inhibiting glucagon release, and promoting weight reduction. Metformin works by decreasing hepatic glucose production and improving insulin sensitivity. This combination is intended to improve glycemic control and support weight management in diabetic patients[1].
- Other names
- TQZ2451 + metformin hydrochloride sustained-release tablets
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)CD274 (Programmed cell death protein 1 ligand 1)Presenilin enhancer protein 2 (PEN-2) / lysosomal vacuolar-type H+-ATPase (v-ATPase) complexGPD2 (Glycerol-3-phosphate dehydrogenase 2)COX7C (Cytochrome c oxidase subunit 7C, mitochondrial)
Beyond the preview
Go deeper on TQZ2451 + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQZ2451 + metformin.